ArticleFrontiers in molecular biosciences2025
Identification of kidney renal clear cell carcinoma prognosis based on gene expression and clinical information.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney renal clear cell carcinoma (KIRC) prognosis exhibits substantial heterogeneity even among patients with identical clinicopathological staging, reflecting the limitations of current classification systems. Therefore, the development of reliable prognostic tools may improve clinical evaluation of KIRC outcomes and facilitate personalized therapy optimization. Methods: The KIRC data of GSE40435 and GSE46699 in the GEO database were immunologically grouped based on 29 immune gene sets through R language. At the same time, RNA sequencing data, clinical information and tumor mutation data of KIRC patients in the TCGA database were jointly processed to explore methods that facilitate clinicians to judge the prognosis of KIRC patients. Quantitative real-time PCR (qPCR) was performed to validate the expression of key prognostic related genes (PRGs) in KIRC and paired adjacent normal tissues. Results: There were significant differences in the immune microenvironment and genetic composition of different immune subtypes of KIRC. A number of high-risk genes related to KIRC prognosis were screened out, and these genes were mainly involved in immune-related functions such as lymphocyte migration. At the same time, we combined TCGA and GEO to find four genes (BASP1, CCL8, FCGR1B, FKBP11) for determining the risk stratification of KIRC, and constructed a model for clinicians to assess KIRC prognosis based on gene expression and clinical information. qPCR confirmed that BASP1, FCGR1B, and FKBP11 were significantly upregulated in KIRC compared to adjacent normal tissues, whereas CCL8 showed no significant differential expression between KIRC and paracancerous tissues. Conclusion: Our study has the potential to assist clinicians assess KIRC prognosis and modify more appropriate personalized treatment for KIRC patients in a timely manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.